A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma

Published:2013-10-05 Issue:10 Volume:14 Page:949-961
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Tula-Sanchez Ana A,Havas Aaron P,Alonge Peter J,Klein Mary E,Doctor Samantha R,Pinkston William,Glinsmann-Gibson Betty J,Rimsza Lisa M,Smith Catharine L

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.25941

Reference76 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

2. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

3. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

4. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

5. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications;Advanced Healthcare Materials;2024-06-28

2. Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma;Translational Oncology;2024-01

3. New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.;Translational Oncology;2023-11

4. Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824;International Journal of Molecular Sciences;2023-09-04

5. Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma;Clinical and Translational Medicine;2022-05